Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07805200
Recruiting Not applicable

Efficacy and Mechanism of Transcranial Temporal Interference Stimulation (tTIS) for Patients With Obsessive-Compulsive Disorders

NCT07805200 · tracked via the Priya Life Science China tracker
Sponsor
Beijing HuiLongGuan Hospital
Phase
Not applicable
Started
2026-10-16
Last updated
2026-09-04

Condition(s) studied

Obsessive - Compulsive Disorder

Investigational drug(s) / intervention(s)

Transcranial Temporal Interference Stimulation

Transcranial Temporal Interference Stimulation: Transcranial temporal interference stimulation (tTIS) is a novel neurostimulation technique that utilizes two or more electric fields of specific frequencies to modulate the oscillations of neurons at the desired spatial location in the brain. The physics of tTIS offers the advantage of noninvasively regulating deep brain structures and minimally stimulating the overlying cortex outside the selected target.

Study summary

Targeted temporal interference stimulation (tTIS) of the nucleus accumbens (NAc) may modulate the abnormal electrophysiological activity in individuals with obsessive-compulsive disorder (OCD), thereby improving their obsessive-compulsive symptoms.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Were between 18 and 65 years old; * Were diagnosed with OCD by an experienced psychiatrist utilizing the Structured Clinical Interview for DSM-5 (SCID); * Were able to participate in the entire trial and face-to-face on-site assessment Exclusion Criteria: * Pregnant or breastfeeding; * Suffered from organic brain diseases or severe physical illness; * Had a history of substance or alcohol abuse; * Presence of comorbid psychiatric disorders (e.g., major depressive disorder) or a high risk of suicide; * Have received electroconvulsive therapy, transcranial magnetic stimulation, tDCS, tACS, or other neurostimulation treatments within the past 6 months; * Presence of contraindications to MRI or tTIS, such as severe head trauma, prior brain surgery, intracranial or cardiac metallic implants, etc.

Primary outcome measure(s)

  • Obsessive-compulsive symptoms — Baseline, immediately after completion of the 5-day intervention (Day 5), and at 1-week, 1-month, and 3-month follow-up
    Obsessive-compulsive symptom severity will be assessed using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). The Y-BOCS total score ranges from 0 to 40, with higher scores indicating greater symptom severity.

Trial sites (1)

FacilityCityRegionStatus
The Fourth People's Hospital of Anhui Province Hefei Anhui Recruiting

More Beijing HuiLongGuan Hospital trials in China

Compassion-Based Family Intervention for Adolescents Recruiting
Study on Mental Health Promoting Effects of Natural Psychotherapy for Adolescents Starting soon
Research on New Methods and New Models of Rehabilitation Intervention for Cancer Patients Based on Exercise and Psychological Intervention Active, not recruiting
Efficacy and Underlying Mechanisms of Group Natural Psychotherapy for Anxiety Symptoms Recruiting

Other trials for the same condition

Accelerated rTMS Therapeutic Approach for Refractory Obsessive-Compulsive Disorder Recruiting
Effect of a Family-Based CBT Self-Help Intervention for Adolescents With OCD Recruiting
Efficacy and Influencing Factors of ALIC-NAc Deep Brain Stimulation in Treatment-Refractory Obsessive-Compulsive Disorder Recruiting
Tracking Risk in Adolescents and Children for Early Identification of Common Mental Disorders Starting soon
Neural Mechanisms of the Sensorymotor Circuit in Sensory Phenomena in OCD Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07805200 on ClinicalTrials.gov ↗ ← All trials in China